Direct-acting antivirals for HCV-related hepatocellular carcinoma reduces the risk of tumor progression

In a new cohort study of patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC), a disease with a high recurrence rate, researchers at the Osaka City University Graduate School of Medicine reported that after receiving cancer treatment, the oral administration of direct-acting antivirals (DAA) reduces the risk of tumor progression following recurrence of the liver disease.

Related Keywords

Osaka ,Japan ,Barcelona ,Comunidad Autonoma De Cataluna ,Spain ,Sawako Uchida Kobayashi ,Norifumi Kawada ,Hiroko Ikenaga ,Emily Henderson ,Department Of Hepatology ,Osaka City University Graduate School Of Medicine ,Osaka City University Graduate School ,Barcelona Clinic Liver Cancer ,Lecturer Sawako Uchida Kobayashi ,Cancer ,Hepatitis ,Hepatitis C ,Liver ,Liver Cancer ,Virus ,Cancer Treatment ,Arcinoma ,Hepatocellular Carcinoma ,Liver Disease ,Medicine ,Ortality ,Research ,Humor ,